Clinical outcome of ultrasound‑guided percutaneous microwave ablation on colorectal liver metastases

Wang,Jianbin; Liang,Ping; Yu,Jie; Yu,Ming‑An; Liu,Fangyi; Cheng,Zhigang; Yu,Xiaoling

doi:10.3892/ol.2014.2106

Clinical outcome of ultrasound‑guided percutaneous microwave ablation on colorectal liver metastases

Authors:
- Jianbin Wang
- Ping Liang
- Jie Yu
- Ming‑An Yu
- Fangyi Liu
- Zhigang Cheng
- Xiaoling Yu
View Affiliations

Affiliations: Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: April 29, 2014 https://doi.org/10.3892/ol.2014.2106
Pages: 323-326

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the feasibility, safety and efficiency of ultrasound‑guided percutaneous microwave ablation (MWA) on liver metastases from colon or rectal cancer. Patients who received MWA therapy for liver metastases from colon or rectal cancer between June 2009 and May 2012 were enrolled in the study. Follow‑up data was collected from the patients in order to statistically analyze the adverse effects, concurrent disease and survival status. Of the total 115 patients, 62 presented with colon cancer and 53 with rectal cancer. A total of 78 patients were male and 37 were female. The patient age ranged between 30 and 86 years [mean ± standard deviation (SD), 59.46±11.79 years]. The number of overall ablation lesions was 165, and the diameter of the lesions ranged between 1.3 and 5.0 cm (mean ± SD, 3.10±1.05 cm). Subsequent to treatment, the mean (± SD) hospitalization time was 4.69±2.08 days (range, 2‑10 days). The median follow‑up time was 28 months (range, 12‑48 months) and 5 patients were lost to follow‑up. The pain grade was recorded between the 4th and 6th degree following treatment in 23 patients. The body temperatures of 35 patients reached >38˚C, with the longest time at this temperature recorded as 5 days. Following treatment, 5 patients presented with pleural effusion and required thoracocentesis and drainage. Following ablation, the rate of local progression was 11.82%. The recurrence rates were 27.8, 48.4 and 59.3% and the cumulative survival rates were 98.1, 87.1 and 78.7% in years 1, 2 and 3 post‑treatment, respectively. A total of 14 patients succumbed. No significant differences were observed in the liver metastases of colorectal cancer with regard to gender, age, number of lesions, lesion size and pathological differentiation (P>0.05). Also, no significant difference was observed in the recurrence or cumulative survival rates for years 1, 2 and 3 years post‑treatment (P>0.05). In conclusion, ultrasound‑guided percutaneous MWA is a safe and competent way to treat inoperable colorectal liver metastases.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 244:254–259. 2006.
3	Wu YZ, Li B, Wang T, Wang SJ and Zhou YM: Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol. 17:4143–4148. 2011.
4	Gillams AR and Lees WR: Radiofrequency ablation of colorectal liver metastases. Abdom Imaging. 30:419–426. 2005.
5	Wright AS, Sampson LA, Warner TF, Mahvi DM and Lee FT Jr: Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 236:132–139. 2005.
6	McWilliams JP, Lee EW, Yamamoto S, Loh CT and Kee ST: Image-guided tumor ablation: emerging technologies and future directions. Semin Intervent Radiol. 27:302–313. 2010.
7	Dong BW, Liang P, Yu XL, et al: Sonographically guided microwave coagulation treatment of liver cancer: an experimental and clinical study. AJR Am J Roentgenol. 171:449–454. 1998.
8	Liang P, Wang Y, Yu X and Dong B: Malignant liver tumors: treatment with percutaneous microwave ablation - complications among cohort of 1136 patients. Radiology. 251:933–940. 2009.
9	Cummings LC, Payes JD and Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 109:718–726. 2007.
10	de Haas RJ, Wicherts DA, Andreani P, et al: Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg. 253:1069–1079. 2011.
11	Leonard GD, Brenner B and Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 23:2038–2048. 2005.
12	Kemeny N: Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 12:825–839. 2007.
13	Martin RC, Robbins K, Tomalty D, et al: Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 7:802009.
14	Hur H, Ko YT, Min BS, et al: Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 197:728–736. 2009.
15	Pathak S, Jones R, Tang JM, et al: Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. 13:e252–e265. 2011.
16	Van Tilborg AA, Meijerink MR, Sietses C, et al: Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 84:556–565. 2011.
17	Siperstein AE, Berber E, Ballem N and Parikh RT: Survival after radio-frequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 246:559–567. 2007.
18	Sørensen SM, Mortensen FV and Nielsen DT: Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol. 48:253–258. 2007.
19	Gwak JH, Oh BY, Lee RA, Chung SS and Kim KH: Clinical applications of radio-frequency ablation in liver metastasis of colorectal cancer. J Korean Soc Coloproctol. 27:202–210. 2011.
20	Wong SL, Mangu PB, Choti MA, et al: American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 28:493–508. 2010.
21	Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pélissier S and Evrard S: Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol. 34:185–190. 2008.
22	Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD and Pawlik TM: Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg. 143:1204–1212. 2008.
23	Vogl TJ, Zegelman A, Bechstein WO, Zeuzem S and Zangos S: Treatment of liver metastases of colorectal carcinoma: overview of hyperthermal ablation methods. Dtsch Med Wochenschr. 138:792–798. 2013.(In German).
24	Yu J, Liang P, Yu X, Liu F, Chen L and Wang Y: A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol. 79:124–130. 2011.
25	Gravante G, Ong SL, Metcalfe MS, Strickland A, Dennison AR and Lloyd DM: Hepatic microwave ablation: a review of the histological changes following thermal damage. Liver Int. 28:911–921. 2008.
26	Li M, Yu XL, Liang P, Liu F, Dong B and Zhou P: Percutaneous microwave ablation for liver cancer adjacent to the diaphragm. Int J Hyperthermia. 28:218–226. 2012.
27	Yu J, Liang P, Yu XL, Cheng ZG, Han ZY and Dong BW: Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. Eur J Radiol. 81:2495–2499. 2012.